Manufacturing Chemist
  • Home
  • Categories
    • Ingredients
    • Analysis
    • Manufacturing
    • Finance
    • Company News
    • Regulatory
    • Drug Delivery
    • Research & Development
    • Sustainability
  • Pharma 5.0
  • Events
  • Directory
  • Editorial team
  • Search
    • Close search
  • Subscribe
  • Login
    • Password
      Password
      Forgot password? Close login form

Market Reports

Cell and gene therapies: on the brink of commercialisation

Cell and gene therapies: on the brink of commercialisation

With their one-and-done potential and pinpoint targeting capability, cell and gene therapies (CGTs) offer huge promise in the fight against a range of previously untreatable diseases. Yet, investment in this sector is not taken lightly. Typically, developers must invest billions of dollars in therapies that might take 10 years to reach the market as they battle the odds against high failure rates
Inspiration from unexpected places

Inspiration from unexpected places

How pharmaceutical companies can learn from advances in nicotine delivery
Overcoming hurdles in the biopharmaceutical pipeline with advanced analytics

Overcoming hurdles in the biopharmaceutical pipeline with advanced analytics

In conversation with Nick Pittman and Magnus Wetterhall, both Global Marketing Managers, Bioprocessing, at Waters Corporation, Dr Kevin Robinson explored some of the big issues associated with manufacturing biologics, how they can be overcome and what Waters is doing to help scientists expedite the process of developing new therapies for patients in need
Treating infection with precise medicine may prevent our next pandemic

Treating infection with precise medicine may prevent our next pandemic

Antimicrobial resistance (AMR) is a grave concern that the scientific and medical community have been warning the public about for decades. There have been no new antibiotics for 35 years and no truly effective incentive for drug makers to develop them, making this threat even more urgent. As the COVID-19 pandemic demonstrated, preparedness could save countless lives and the world’s economy
Optimising coating process parameters and formulation concepts for functional taste-masking during continuous manufacturing

Optimising coating process parameters and formulation concepts for functional taste-masking during continuous manufacturing

This article describes work done to optimise the coating process parameters (spray rate, inlet air temperature, inlet airflow), formulation and functionality of a taste-masking coat for oral solid dosage forms during continuous production
Dissolution testing: an established technique driving advances in drug delivery

Dissolution testing: an established technique driving advances in drug delivery

This article introduces dissolution testing and highlights its ability to support modern formulation challenges. Pharmacopoeial methods are discussed with reference to specific apparatuses and method parameters. Dissolution testing equipment from Copley Scientific is showcased to illustrate the performance and productivity that are accessible with well-designed, cost-effective solutions
COVID-19: focusing attention on the next transformation in healthcare

COVID-19: focusing attention on the next transformation in healthcare

The lightning-fast global spread of the Omicron variant of COVID-19 was a painful reminder that the only way to protect against the disease is vaccination on a global level. At the same time, South African researchers’ quick identification and analysis of Omicron demonstrated the strength and interconnectedness of the international science community, with critical data rapidly passed to those who were best able to mount a response
Manufacturing Chemist LIVE 2022 in review (part I)

Manufacturing Chemist LIVE 2022 in review (part I)

Taking a front row seat during the two-day pharmaceutical conference in Birmingham, UK, Dr Kevin Robinson reports on what’s new, emerging and exciting in the world of drug delivery and beyond
Native mass spectrometry as a drug discovery engine

Native mass spectrometry as a drug discovery engine

Using mass spectrometry to characterise and screen large intact protein targets, captured directly in their native state, is making waves as a differentiated approach to hit finding in drug discovery, explains Dr Jonathan T.S. Hopper, founder and VP of Platforms at OMass Therapeutics
Transforming tomorrow

Transforming tomorrow

Shaping the future with better processes, GEA has responded to the impact that digitalisation is having on the pharmaceutical manufacturing industry and pioneered a suite of virtual technologies that improve the customer experience
Chemistry meets biology: an integrated approach to developing and manufacturing medicines of the future

Chemistry meets biology: an integrated approach to developing and manufacturing medicines of the future

Until recently, chemists and biologists rarely needed to collaborate to develop a new large molecule drug, reports Chris Conway, President, Research and Development, Curia
Closing the gap between biotherapies and their quality control

Closing the gap between biotherapies and their quality control

NGS-based biosafety tests are giving the biomanufacturing industry a facelift
Droplet microfluidics: leveraging the untapped potential of single-cell research and high-throughput screening

Droplet microfluidics: leveraging the untapped potential of single-cell research and high-throughput screening

The age of personalised medicine requires modern tools. Recent research breakthroughs such as the meteoric rise of CRISPR technology and the emergence of single-cell sequencing have clearly shown a vast untapped potential in the life sciences, reports Juozas Nainys, CEO of Droplet Genomics
A smart approach to ready-to-use drug containment solutions

A smart approach to ready-to-use drug containment solutions

At a time when global healthcare providers are coming under previously unknown levels of pressure, their suppliers need to react with greater speed and flexibility to meet demand without compromising patient safety
Influence of material and capsule filling process on DPI aerosolisation performance

Influence of material and capsule filling process on DPI aerosolisation performance

The effect of capsule filling parameters on emitted dose and fine particle fraction by a DPI was investigated using a benchtop capsule filling device. Compression was the parameter that affected weight and emitted fraction the most, whereas the type of coarse lactose seems to influence the fine particle fraction
Bringing biotech to the Baltics: the rise of Lithuania

Bringing biotech to the Baltics: the rise of Lithuania

Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a still-unsaturated market. Dr Kevin Robinson spoke with the country’s Minister for Economy and Innovation, Aušrinė Armonaitė, to find out more
  • Previous
  • 1
  • 2
  • 3
  • 4 (current)
  • 5
  • 6
  • 7
  • …
  • 15
  • Next

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Terminal sterilisation versus aseptic filling: ensuring drug product safety The sterility of drug products is critical to patient safety. Choosing between terminal sterilisation or aseptic processing to achieve this should reflect the final product’s physical attributes, the required sterility assurance and contamination-control regulations such as EU GMP Annex 1
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    US mRNA policy shift: are vaccine headwinds accelerating oncology focus? With Washington’s stance on mRNA vaccines cooling, Manufacturing Chemist examines whether policy and funding signals could influence the pharmaceutical industry’s most commercially promising frontier: oncology therapeutics
  3. Panthera joins the Association of Multisite Research Corporations (AMRC) Membership strengthens Panthera’s ability to collaborate across the industry, contribute to collective advocacy and help shape the future of clinical research
  4. Empowering patients with self-administration drug delivery devices Incorporating self-administered drug-device combination products into clinical trials benefits patients and manufacturers alike, reports Bill Welch, Executive Director of Market Development at PCI Pharma Services
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    From stockpiles to smart supply chains: how industry wants to fix Europe’s drug shortages An EU-level stockpile may work, but only if it’s flexible, closely monitored and built with logistics in mind. Industry players say drug security will depend less on volume and more on data, digital oversight and early collaboration throughout the supply chain

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy
See all

Become a Subscriber

Subscribe now Already a subscriber? Sign in here. Find out more

Get our newsletter

Follow us

  • LinkedIn
  • About Manufacturing Chemist
  • About HPCi Media
  • Newsletter sign up
  • Contact Us
  • Advertise
  • Terms and Conditions
  • Privacy
© HPCi Media Limited | Registered in England No. 06716035 | VAT GB 939828072 | a Claverley Group company Registered office address:
One Anchorage Avenue,
Shrewsbury Business Park,
Shrewsbury,
SY2 6FG, UK.